Date: 2015-09-19
Type of information: Nomination
Compound:
Company: Arsanis (USA - MA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 19, 2015, Arsanis, a development stage biopharmaceutical company focused on monoclonal antibody therapeutics for severe infectious diseases, announced the appointment of Rene Russo, PharmD, BCPS as Chief Development Officer. Dr. Russo, most recently Vice President, Global Medical Affairs at Cubist Pharmaceuticals (acquired by Merck in 2015), will be a member of the Arsanis executive team and will provide strategic planning and leadership for the clinical development of ASN100, Arsanis’ lead program for the prevention and treatment of severe Staphylococcus aureus infections, and other pipeline product candidates. Over the course of her career, Dr. Russo was directly involved in the development of over 10 anti-infective agents as well as global commercial product launches for 5 novel antibacterial agents.
Arsanis also announced the appointments of Dan Burgess and Amy Schulman to its Board of Directors. Dan Burgess is currently a Venture Partner with SV Life Sciences and was previously the Founder, President and Chief Executive Officer of Rempex Pharmaceuticals, Inc., prior to its acquisition by the Medicines Company. Amy Schulman is currently a Venture Partner with Polaris Partners and CEO of Lyndra and Arsia Therapeutics. She was previously responsible for leading Pfizer, $4 billion Consumer Healthcare business and held roles as Executive Vice President and General Counsel of Pfizer, Inc., amongst others.
Financial terms:
Latest news:
